MRTX - Mirati Therapeutics, Inc.
78.34 -2.02 (-2.52%)
After hours: 4:11PM EDT
| Previous Close | 78.45 |
| Open | 78.30 |
| Bid | 80.45 x 1100 |
| Ask | 80.47 x 800 |
| Day's Range | 75.16 - 80.51 |
| 52 Week Range | 28.50 - 111.99 |
| Volume | 568,107 |
| Avg. Volume | 522,327 |
| Market Cap | 3.158B |
| Beta (3Y Monthly) | 2.81 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.18 |
| Earnings Date | Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 110.92 |
- Bloomberg
After 500% Surge, Mirati’s Day of Reckoning Is Approaching
(Bloomberg) -- With no drugs on the market and no earnings to speak of, Mirati Therapeutics Inc. has soared more than 500% since September 2017.That’s when the oncology company’s lead product, sitravatinib, showed early promise in lung cancer. But even with a pivotal study for the treatment already in motion, investors have set their sights elsewhere: a yet-to-be proven experimental therapy known only as MRTX849.While Mirati has only guided to a first look at MRTX849 sometime in the fourth quarter, sell-side analysts expect results to be presented as late-breaking data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, a meeting in Boston that kicks off at the end of the month.MRTX849 targets a mutation on the KRAS gene, which in human tumors can spur cancer’s growth. It occurs in about 13% of non-small cell lung cancers and 3% of colon cancers, as well as handful of other tumors. Doctors have long-called the KRAS gene “undruggable,” an impervious target where treatments couldn’t get a foothold. That changed this summer, when Amgen Inc. revealed early data for its rival molecule. Amgen’s AMG 510 spurred a partial response in a handful of lung cancer patients, though the disease returned after a few months in some of them.That promising signal from Amgen was enough to send Mirati’s stock to a record $109.60 a share on July 3, despite a lack of any clinical data for its KRAS drug. Bulls believe MRTX849 may last longer in the body and therefore be more effective than Amgen’s AMG 510. But investor concerns have crept back into shares of both companies after another look at AMG 510 showed that the highest dose helped shrink colon cancer in only one out of 12 patients.Mirati investors have to ask if the disappointing colon cancer response is specific to AMG 510 or applies to the whole KRAS class, SVB Leerink analyst Andrew Berens said in a phone interview. Berens, who rates Mirati outperform, says dosing is Amgen’s Achilles’ heel, making it hard to get high concentrations of AMG 510 into patients. “If you don’t get enough of the drug into the tissue, you aren’t going to get complete efficacy,” he cautioned. Berens doesn’t cover Amgen; the stock is rated market perform by another Leerink analyst.Wall Street has been bullish to neutral on Mirati with one exception: JPMorgan’s Anupam Rama. He gave the San Diego, California-based company its first ever sell-equivalent rating in August, shortly after Mirati reached a record. Expectations were too high and the downside was underappreciated, Rama warned clients in a note. Even if Mirati shows response rates as high as 60% -- similar to AMG 510 in lung cancer -- that could be viewed as a “downside scenario,” he wrote recently.Rama said some investors may look on Mirati as a buyout target even if its results are merely comparable to Amgen’s data. He argues a takeover is unlikely to happen until its drug has established “some reasonable durability,” and that will take time. Rama expects Mirati’s medicine could ultimately outperform AMG 510 on the length of responses and how long patients live before their disease gets worse. The problem -- and the basis for Rama’s underweight call -- is the evidence isn’t likely to emerge during the first look at Mirati’s drug, and questions over durability won’t be answered in the near future. Mirati’s market valuation was just shy of $3 billion as of Friday’s close.Meanwhile, competition has been heating up. Johnson & Johnson started its own study, as has the closely held German company, Boehringer Ingelheim GmbH. Boehringer will study its KRAS-inhibitor alone as well as in combination with other cancer drugs, an area where Amgen has also expressed interest.Bearish bets against Mirati stand at 15% of the drugmaker’s float, according to S3 Partners data. Options in Mirati set to expire on Oct. 18 show investors expect shares to move about 13% over the next two weeks. The at-the-money straddle set to expire in November is showing an expected price move of 34%. Implied volatility is elevated at about 129% versus a 90-day average of 70.\--With assistance from Gregory Calderone.To contact the reporter on this story: Cristin Flanagan in New York at cflanagan1@bloomberg.netTo contact the editors responsible for this story: Catherine Larkin at clarkin4@bloomberg.net, Michelle Fay CortezFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks
Are Options Traders Betting on a Big Move in Mirati Therapeutics (MRTX) Stock?
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
- Simply Wall St.
Here's Why We're Not Too Worried About Mirati Therapeutics's (NASDAQ:MRTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Zacks
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
- Motley Fool
4 Biotech Stocks With Big Catalysts in September
Two presentations at the World Conference on Lung Cancer will make a big difference for at least four different drugmakers.
- GuruFocus.com
Mirati Therapeutics Inc (MRTX) President & CEO Charles M Baum Sold $4.5 million of Shares
President & CEO of Mirati Therapeutics Inc (30-Year Financial, Insider Trades) Charles M Baum (insider trades) sold 51,810 shares of MRTX on 08/22/2019 at an average price of $86.22 a share. Continue reading...
- Simply Wall St.
A Look At The Intrinsic Value Of Mirati Therapeutics, Inc. (NASDAQ:MRTX)
Today we will run through one way of estimating the intrinsic value of Mirati Therapeutics, Inc. (NASDAQ:MRTX) by...
- PR Newswire
Mirati Therapeutics Appoints Jenny Gizzi As Vice President, Human Resources
SAN DIEGO, Aug. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced the appointment of Jenny Gizzi as Vice President, Human Resources, reporting directly to Charles M. Baum, M.D., Ph.D., President and Chief Executive Officer. In her role, Ms. Gizzi will be responsible for all aspects of the Company's human resources operations and strategy, including overseeing the planning, development, implementation and administration of Mirati's human resources programs. This critical perspective will help us maintain our dynamic culture as we further advance our programs and continue our growth into a premier targeted oncology company," said Dr. Charles Baum.
- PR Newswire
Mirati Therapeutics Reports Second Quarter 2019 Financial Results
SAN DIEGO , Aug. 5, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the second quarter ended June 30, 2019 ...
- Simply Wall St.
Is Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) CEO Pay Fair?
Charles Baum has been the CEO of Mirati Therapeutics, Inc. (NASDAQ:MRTX) since 2012. This report will, first, examine...
- Zacks
Mirati Inks Deal with Novartis to Evaluate Tumor Candidate
Mirati (MRTX) inks a clinical collaboration with Novartis to evaluate the combination of the former's MRTX849 and the latter's SHP2 inhibitor, TNO155, in patients with advanced solid tumors.
- Investor's Business Daily
How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug
A collaboration with Swiss pharma giant Novartis could validate an experimental cancer treatment from biotech company Mirati Therapeutics, an analyst said Wednesday as Mirati stock rose.
- Benzinga
The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 9) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Athenex ...
- PR Newswire
Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155
SAN DIEGO, July 9, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, today announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumors that harbor KRAS G12C mutations. SHP2 is an important mediator of cellular signaling through the RAS/MAP kinase pathway and is frequently overactive in various types of cancer.
- Benzinga
The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...
- PR Newswire
Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, today announced the appointment of Dr. Julie Cherrington, Ph.D. to its Board of Directors, effective June 27, 2019. Dr. Cherrington has extensive experience in oncology drug development and has played a key role in the development of several FDA-approved products. "Julie brings deep expertise in targeted oncology to the Board of Directors.
- Motley Fool
3 Top Biotech Stocks to Buy Right Now
These three biotech stocks should be outstanding long-term growth vehicles.
- PR Newswire
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO, June 27, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the closing of its previously announced underwritten public offering of 2,415,000 shares of its common stock at a public offering price of $97.00 per share. Cowen, Credit Suisse and Barclays acted as joint book-running managers in the offering. The shares of common stock described above were offered by Mirati pursuant to a shelf registration statement filed by Mirati with the Securities and Exchange Commission ("SEC") that became automatically effective upon filing.
- PR Newswire
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, June 25, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 2,100,000 shares of its common stock at a price to the public of $97.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $203.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has also granted the underwriters a 30-day option to purchase up to an additional 315,000 shares of common stock in connection with the public offering.
- PR Newswire
Mirati Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 24, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Mirati. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.
- Motley Fool
Read This Before You Buy Any New Cancer Drug Stocks
Around $36 billion worth of biopharma acquisitions over the past few years suggests smaller might be better.
- Zacks
Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
- Investopedia
3 Under-the-Radar Stocks Trading at All-Time Highs
These lesser-known mid-cap stocks are posting stronger returns than the majority of widely held plays touted in the financial media.
